망막모세포종 치료 시장 보고서 : 유형별, 치료 유형별, 병기별, 용도별, 지역별(2025-2033년)

The global retinoblastoma treatment market size reached USD 3.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.1 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. A considerable rise in healthcare expenditure for ophthalmic treatment procedures, increasing investments in research and development (R&D) activities on therapies with lower side effects, and the increasing health consciousness represent some of the key factors driving the market.

Retinoblastoma is one of the most common cancers that generally develops before the age of 5 in children. Some of the symptoms of retinoblastoma include a white appearance in the pupil called cat's eye reflex or leukocoria. Retinoblastoma treatment can include a variety of drug delivery and chemotherapy techniques that provide some benefits in the short term since retinoblastoma is curable at the initial stage. Following the first or second chemotherapy cycle, different focal treatments can then be applied depending on how much the tumor shrinks and where it is in the eye. A combination of different treatment methods is the most successful retinoblastoma treatment option. Surgery is the permanent retinoblastoma treatment option as it removes the tumor thoroughly from the retina. There are a variety of imaging tests available for a detailed diagnosis of retinoblastoma, including ultrasound, CT-scan, MRI, X-ray, and bone scan.

Retinoblastoma Treatment Market Trends:

A considerable rise in healthcare expenditure for ophthalmic treatment procedures is a significant factor driving the market. This can be attributed to the rising incidences of retinoblastoma among the younger population. In line with this, increasing investments in research and development (R&D) activities focusing on newer, more efficient therapeutic strategies with lesser associated side effects is providing an impetus to the market. Moreover, the growing awareness regarding different type of cancers resulting in higher diagnosis and treatment rates are also acting as a significant growth-inducing factor. However, the lack of availability of various retinoblastoma treatment drugs, along with stringent drug regulations, are acting as a growth-restraining factor for the market. On the contrary, the increasing number of product approvals leading to the launches of new drug variants is creating a positive outlook for the market. Besides this, the growing rates of recurrence of retinoblastoma are also creating lucrative opportunities in the retinoblastoma treatment market. The market is further propelled by various organic growth strategies undertaken by key payers, such as partnerships and collaborations, and merger and acquisitions (M&As). Apart from this, the presence of strong pipeline drugs, along with the augmenting number of clinical trials, are fueling the market growth. Some of the other factors contributing to the market include rapid urbanization, inflating disposable income levels, considerable growth in cancer research, and improvements in medical infrastructure across the globe.

Key Market Segmentation:

Type Insights:

• Non-Hereditary Retinoblastoma
• Hereditary Retinoblastoma

Treatment Type Insights:

• Surgery
• Radiation Therapy
• Laser Therapy (Photocoagulation)
• Cryotherapy
• Thermotherapy
• Chemotherapy
• Opthalmic Artery Infusion Chemotherapy
• High-Dose Chemotherapy and Stem Cell Transplant

Type of Staging Insights:

• Intraocular Retinoblastoma
• Extraocular Retinoblastoma

Application Insights:

• Hospitals
• Cancer Institutes
• Others

Regional Insights:

• North America
• United States
• Canada
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
• The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Asia Pacific was the largest market for retinoblastoma treatment. Some of the factors driving the Asia Pacific retinoblastoma treatment market include the growing rates of recurrence of retinoblastoma, higher diagnosis and treatment rates due to the increasing awareness regarding different types of cancers, the presence of several key players in the region, etc.

Competitive Landscape:

• The report has also provided a comprehensive analysis of the competitive landscape in the global retinoblastoma treatment market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Bristol Myers Squibb Company, Pfizer Inc., Teva Canada Limited (Teva Pharmaceutical Industries Ltd.), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

• How has the global retinoblastoma treatment market performed so far and how will it perform in the coming years ?
• What are the drivers, restraints, and opportunities in the global retinoblastoma treatment market ?
• What are the key regional markets ?
• Which countries represent the most attractive retinoblastoma treatment markets ?
• What is the breakup of the market based on the type ?
• What is the breakup of the market based on the treatment type ?
• What is the breakup of the market based on the type of staging ?
• What is the breakup of the market based on application ?
• What is the competitive structure of the global retinoblastoma treatment market ?
• Who are the key players/companies in the global retinoblastoma treatment market ?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Retinoblastoma Treatment Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Non-Hereditary Retinoblastoma
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Hereditary Retinoblastoma
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Treatment Type

• 7.1 Surgery
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Radiation Therapy
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Laser Therapy (Photocoagulation)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Cryotherapy
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Thermotherapy
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Chemotherapy
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast
• 7.7 Opthalmic Artery Infusion Chemotherapy
  • 7.7.1 Market Trends
  • 7.7.2 Market Forecast
• 7.8 High-Dose Chemotherapy and Stem Cell Transplant
  • 7.8.1 Market Trends
  • 7.8.2 Market Forecast

8 Market Breakup by Type of Staging

• 8.1 Intraocular Retinoblastoma
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Extraocular Retinoblastoma
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Application

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Cancer Institutes
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 Drivers, Restraints, and Opportunities

• 11.1 Overview
• 11.2 Drivers
• 11.3 Restraints
• 11.4 Opportunities

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Bristol Myers Squibb Company
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
    • 15.3.1.4 SWOT Analysis
  • 15.3.2 Pfizer Inc.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Teva Canada Limited (Teva Pharmaceutical Industries Ltd.)
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report